Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8518MR)

This product GTTS-WQ8518MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8518MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ417MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ1619MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ7331MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ15673MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ2614MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ3347MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ7834MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ13347MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06801591
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW